Volume Alert - AGIO 94.60 Agios Pharmaceuticals In
Post# of 89358
Posted On: 11/19/2014 1:04:44 PM
Volume Alert - AGIO 94.60 Agios Pharmaceuticals Inc $AGIO Hit a high today of 95.18 Closing the day 10:30 at 94.60 +10.79 +12.87% With a day low of 83.68 and a total volume of 1,790,245.
AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/
AGIO Agios Pharmaceuticals Inc Recent Headline News
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 8 mins ago
CLUB: 6.06 (+0.51), LEJU: 12.23 (-1.93), ANV: 1.77 (-0.27), SSI: 18.62 (+2.88), ROX: 1.53 (-0.25), CLF: 8.75 (-1.46), BIND: 8.57 (-1.98), NADL: 3.29 (-0.68), CSTM: 17.01 (-3.96), VRML: 1.48 (+0.11), WTT: 2.63 (-0.28), CANF: 3.95 (+0.95), DL: 17.98 (+3.01), BAMM: 1.79 (+0.22), RELV: 1.32 (+0.13), SNCR: 42.45 (-5.16), ATLC: 2.64 (+0.33), AGIO: 95.61 (+11.80), BBLU: 1.09 (-0.10), OPLK: 24.18 (+2.93)
Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'
at The Street - 1 hr 42 mins ago
TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)
Stock Futures Take A Data Dive; Tesla Falls On Outlook Change
at Investor's Business Daily - Wed Nov 19, 8:11AM CST
Stock futures fell out of flat trade to moderate losses ahead of Wednesday's open after a mixed read on October homebuilding activity. Dow futures slumped 18.8 points below fair market value. Nasdaq 100 futures traded down 6.3 points. S&P 500 futures...
SPLS: 13.90 (+1.14), LEJU: 12.23 (-1.93), TSLA: 248.07 (-9.63), FCAU: 12.29 (-0.52), LITB: 7.93 (+0.29), TTM: 46.58 (-0.58), DL: 17.98 (+3.01), VA: 36.13 (-0.92), TGT: 72.45 (+4.94), GM: 32.20 (-0.07), AGIO: 95.61 (+11.80), LOW: 62.37 (+3.84), HMC: 31.17 (-0.48), EJ: 8.67 (-0.86), PETM: 77.21 (+3.59)
Agios leukemia drug candidate shows clinical activity in Phase 1 trial
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:01AM CST
AGIO: 95.61 (+11.80)
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)
Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Nov 18, 5:01PM CST
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -
AGIO: 95.61 (+11.80)
Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 17.06 (unch), SIX: 40.07 (-0.73), AGIO: 95.61 (+11.80)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 83.23 (-2.33), OREX: 5.72 (+0.10), PCMI: 8.95 (+0.16), CYAN: 7.35 (-0.49), ACHN: 13.19 (-0.12), TGTX: 14.70 (-0.07), AGIO: 95.61 (+11.80), LIOX: 5.02 (-0.12), SAJA: 5.75 (-0.22), PLNR: 7.20 (-0.19)
Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST
XBI: 172.16 (+0.78), SLXP: 106.16 (+0.77), ICPT: 156.71 (-5.79), IBB: 296.33 (+1.08), AGIO: 95.61 (+11.80)
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST
AGIO: 95.61 (+11.80)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST
BEBE: 2.57 (unch), ANET: 76.88 (+0.08), TKMR: 16.45 (+0.08), ORBC: 6.39 (+0.05), MDRX: 12.08 (-0.12), RMTI: 10.09 (-0.19), CTIC: 2.23 (-0.05), SHLD: 34.88 (-1.03), UBNT: 29.57 (-0.02), RIG: 25.35 (-0.50), KGC: 2.90 (-0.06), APT: 2.83 (+0.10), ANF: 29.11 (+0.17), MITK: 3.91 (-0.05), ZNGA: 2.70 (-0.01), CNET: 1.82 (-0.04), KING: 15.97 (-0.13), NETE: 1.34 (-0.01), SLXP: 106.16 (+0.77), RPRX: 9.14 (-0.05), NADL: 3.31 (-0.66), PGNX: 6.51 (-0.03), AVNR: 13.90 (+0.20), FSLR: 48.67 (-0.79), DVA: 74.79 (-0.44), NDLS: 22.48 (-0.17), ICPT: 156.71 (-5.79), AGIO: 95.61 (+11.80), PLNR: 7.20 (-0.19)
Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST
AGIO: 95.61 (+11.80)
Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 95.61 (+11.80)
Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 95.61 (+11.80)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST
BAM: 49.65 (-0.23), ERF: 15.08 (-0.07), LXP: 10.84 (-0.13), PGEM: 12.34 (-0.09), CCOI: 35.13 (-0.02), TTI: 8.02 (-0.14), SJI: 56.49 (-0.06), NXST: 46.51 (-0.89), VSAT: 65.75 (+0.21), MT: 12.26 (-0.19), LXU: 33.93 (+0.20), HUM: 136.84 (-2.45), PGNX: 6.51 (-0.03), MHR: 4.64 (+0.02), CTB: 32.60 (+0.08), IDRA: 2.55 (+0.07), ISIS: 50.60 (+0.89), BPL: 81.60 (+0.20), SSP: 19.55 (-0.09), AGIO: 95.61 (+11.80), EBIX: 15.99 (-0.24)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 85.02 (-3.78), RNA: 11.51 (+0.01), AGIO: 95.61 (+11.80), CELG: 107.54 (+0.76)
Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 95.61 (+11.80)
Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 114.86 (-0.52), LNKD: 220.27 (-0.80), HAL: 48.06 (-0.48), AGIO: 95.61 (+11.80), IMPV: 41.97 (-0.56)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 102.09 (-1.62), CLVS: 49.01 (-4.77), ARWR: 5.87 (-0.08), ACHN: 13.19 (-0.12), MRK: 59.55 (-0.34), RTRX: 8.48 (-0.55), RGLS: 16.83 (-1.29), EPZM: 22.91 (-0.52), AGIO: 95.51 (+11.70), RMTI: 10.09 (-0.19), ARNA: 4.15 (-0.16), KERX: 15.35 (-0.19)
AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/
AGIO Agios Pharmaceuticals Inc Recent Headline News
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 8 mins ago
CLUB: 6.06 (+0.51), LEJU: 12.23 (-1.93), ANV: 1.77 (-0.27), SSI: 18.62 (+2.88), ROX: 1.53 (-0.25), CLF: 8.75 (-1.46), BIND: 8.57 (-1.98), NADL: 3.29 (-0.68), CSTM: 17.01 (-3.96), VRML: 1.48 (+0.11), WTT: 2.63 (-0.28), CANF: 3.95 (+0.95), DL: 17.98 (+3.01), BAMM: 1.79 (+0.22), RELV: 1.32 (+0.13), SNCR: 42.45 (-5.16), ATLC: 2.64 (+0.33), AGIO: 95.61 (+11.80), BBLU: 1.09 (-0.10), OPLK: 24.18 (+2.93)
Cramer: Agios Pharmaceuticals' Leukemia Drug Pushing Stock 'Much Higher'
at The Street - 1 hr 42 mins ago
TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)
Stock Futures Take A Data Dive; Tesla Falls On Outlook Change
at Investor's Business Daily - Wed Nov 19, 8:11AM CST
Stock futures fell out of flat trade to moderate losses ahead of Wednesday's open after a mixed read on October homebuilding activity. Dow futures slumped 18.8 points below fair market value. Nasdaq 100 futures traded down 6.3 points. S&P 500 futures...
SPLS: 13.90 (+1.14), LEJU: 12.23 (-1.93), TSLA: 248.07 (-9.63), FCAU: 12.29 (-0.52), LITB: 7.93 (+0.29), TTM: 46.58 (-0.58), DL: 17.98 (+3.01), VA: 36.13 (-0.92), TGT: 72.45 (+4.94), GM: 32.20 (-0.07), AGIO: 95.61 (+11.80), LOW: 62.37 (+3.84), HMC: 31.17 (-0.48), EJ: 8.67 (-0.86), PETM: 77.21 (+3.59)
Agios leukemia drug candidate shows clinical activity in Phase 1 trial
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:01AM CST
AGIO: 95.61 (+11.80)
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 95.61 (+11.80), CELG: 107.56 (+0.78)
Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Nov 18, 5:01PM CST
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -
AGIO: 95.61 (+11.80)
Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 17.06 (unch), SIX: 40.07 (-0.73), AGIO: 95.61 (+11.80)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 83.23 (-2.33), OREX: 5.72 (+0.10), PCMI: 8.95 (+0.16), CYAN: 7.35 (-0.49), ACHN: 13.19 (-0.12), TGTX: 14.70 (-0.07), AGIO: 95.61 (+11.80), LIOX: 5.02 (-0.12), SAJA: 5.75 (-0.22), PLNR: 7.20 (-0.19)
Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST
XBI: 172.16 (+0.78), SLXP: 106.16 (+0.77), ICPT: 156.71 (-5.79), IBB: 296.33 (+1.08), AGIO: 95.61 (+11.80)
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST
AGIO: 95.61 (+11.80)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST
BEBE: 2.57 (unch), ANET: 76.88 (+0.08), TKMR: 16.45 (+0.08), ORBC: 6.39 (+0.05), MDRX: 12.08 (-0.12), RMTI: 10.09 (-0.19), CTIC: 2.23 (-0.05), SHLD: 34.88 (-1.03), UBNT: 29.57 (-0.02), RIG: 25.35 (-0.50), KGC: 2.90 (-0.06), APT: 2.83 (+0.10), ANF: 29.11 (+0.17), MITK: 3.91 (-0.05), ZNGA: 2.70 (-0.01), CNET: 1.82 (-0.04), KING: 15.97 (-0.13), NETE: 1.34 (-0.01), SLXP: 106.16 (+0.77), RPRX: 9.14 (-0.05), NADL: 3.31 (-0.66), PGNX: 6.51 (-0.03), AVNR: 13.90 (+0.20), FSLR: 48.67 (-0.79), DVA: 74.79 (-0.44), NDLS: 22.48 (-0.17), ICPT: 156.71 (-5.79), AGIO: 95.61 (+11.80), PLNR: 7.20 (-0.19)
Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST
AGIO: 95.61 (+11.80)
Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 95.61 (+11.80)
Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 95.61 (+11.80)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST
BAM: 49.65 (-0.23), ERF: 15.08 (-0.07), LXP: 10.84 (-0.13), PGEM: 12.34 (-0.09), CCOI: 35.13 (-0.02), TTI: 8.02 (-0.14), SJI: 56.49 (-0.06), NXST: 46.51 (-0.89), VSAT: 65.75 (+0.21), MT: 12.26 (-0.19), LXU: 33.93 (+0.20), HUM: 136.84 (-2.45), PGNX: 6.51 (-0.03), MHR: 4.64 (+0.02), CTB: 32.60 (+0.08), IDRA: 2.55 (+0.07), ISIS: 50.60 (+0.89), BPL: 81.60 (+0.20), SSP: 19.55 (-0.09), AGIO: 95.61 (+11.80), EBIX: 15.99 (-0.24)
Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 85.02 (-3.78), RNA: 11.51 (+0.01), AGIO: 95.61 (+11.80), CELG: 107.54 (+0.76)
Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 95.61 (+11.80)
Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 114.86 (-0.52), LNKD: 220.27 (-0.80), HAL: 48.06 (-0.48), AGIO: 95.61 (+11.80), IMPV: 41.97 (-0.56)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 102.09 (-1.62), CLVS: 49.01 (-4.77), ARWR: 5.87 (-0.08), ACHN: 13.19 (-0.12), MRK: 59.55 (-0.34), RTRX: 8.48 (-0.55), RGLS: 16.83 (-1.29), EPZM: 22.91 (-0.52), AGIO: 95.51 (+11.70), RMTI: 10.09 (-0.19), ARNA: 4.15 (-0.16), KERX: 15.35 (-0.19)
(0)
(0)